RESUMO
Objective To evaluate the conversion of serum antibodies against Schistosoma japonicum in humans and livestock detected by immunological tests following treatment with praziquantel. Methods The studies pertaining to serological tests of schistosomiasis japonica published from 1991 to 2020 were retrieved in electronic databases, including Chinese National Knowledge Infrastructure, WanFang Data, PubMed and ScienceDirect. Data were extracted from included studies. The publication bias was assessed with funnel plots using the software RevMan version 5.3, and the conversion of antibodies against S. japonicum was evaluated through meta-analysis. Results A total of 40 publications were included in the final meta-analysis, consisting of 33 Chinese publications and 7 English publications, and all immunological tests were performed with indirect hemagglutination test (IHA) and enzyme-linked immunosorbent assay (ELISA). Pooled analysis showed that the negative rates of serum anti-S. japonicum antibody were 45.36% [95% confidential interval (CI): (43.96%, 46.76%)] and 20.83% [95% CI: (19.69%, 21.97%)] detected by ELISA and IHA within 6 months post praziquantel treatment, 62.95% [95% CI: (61.59%, 64.31%)] and 55.61% [95% CI: (54.21%, 57.01%)] within 6 to 12 months after treatment and 85.92% [95% CI: (84.94%, 86.90%)] and 86.90% [95% CI: (85.95%, 87.85%)] over 12 months after treatment, respectively. Conclusions The negative rate of the serum anti-S. japonicum antibody by IHA and ELISA increased with the time of post-treatment with praziquantel. The overall negative rates of anti-S. japonicum antibody detected by IHA and ELISA are low within 12 months post praziquantel treatment. However, a high negative rate of anti-S. japonicum antibody is detected if there is no new contact with infested water after 12 months of praziquantel treatment.
RESUMO
PURPOSE: This study was designed to estimate the prevalence of Mycoplasma pneumoniae infection during an epidemic period by means of examining the antibody conversion rate and to investigate the association of the antibody conversion with age, initial antibody titer, and atopy. METHODS: We chose 191 children whose antibody titer to M. pneumoniae was negative, 1:40, or 1:80 during the first half of 2003. After the second half of 2003 when the M. pneumoniae epidemic occurred, follow-up collection of sera was performed during the first half of 2004. M. pneumoniae antibody titer was measured by Serodia-Myco II particle agglutination test. RESULTS: Of 191 children, antibody conversion was detected in 83 children(43.5 percent). No significant difference was found between the conversion and non-conversion group with respect to age, sex and atopy. Dividing the subjects into four groups by age, results on the antibody conversion rate revealed no significant differences between the groups. Assessed by initial antibody titer, a diminished trend of conversion rate was observed in children with 1:80 titer but the difference was not significant. There was no significant difference in the antibody conversion rate between atopic and non-atopic children. CONCLUSION: Based on the antibody conversion rate in this study, the prevalence of M. pneumoniae infection during an epidemic period was estimated to be 43.5 percent. This high infection rate suggests that during an epidemic, we should bear in mind M. pneumoniae as an important etiologic agent for respiratory infection in children.